Skip to main content

Patents

From foundational patents to delivery technology, we have pioneered the development of mRNA medicine since our founding. Along the way, we have accumulated a broad collection of patents, with several hundred additional pending patent applications. 

Intellectual Property

The following articles are protected by the following United States patents for Moderna:


SPIKEVAX® (mRNA-1273 COVID-19 Vaccine)

US 12,208,288

US 11,622,972

US 11,524,023

US 11,485,972

US 10,898,574

US 10,703,789

US 10,702,600

US 10,577,403

US 10,442,756

US 10,266,485

US 10,064,959

US 9,868,692


mRESVIA® (mRNA-1345 Respiratory Syncytial Virus Vaccine)

US 11,622,972

US 11,524,023

US 11,464,848

US 10,898,574

US 10,703,789

US 10,577,403

US 10,442,756

US 10,266,485

US 10,064,959

US 9,868,692


mNEXSPIKE® (mRNA-1283 COVID-19 Vaccine)

US 11,622,972

US 11,524,023

US 10,898,574

US 10,703,789

US 10,577,403

US 10,442,756

US 10,266,485

US 10,064,959

US 9,868,692


In addition, Moderna owns additional patents in the United States and foreign jurisdictions.